Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Chen, Yaoqing ^a   Cao, Luyang ^a   Zhong, Maohua ^b   Zhang, Yan ^b   Han, Chen ^b   Li, Qiaoli ^b   Yang, Jingyi ^b   Zhou, Dihan ^b   Shi, Wei ^b   He, Benxia ^b   Liu, Fang ^b   Yu, Jie ^b   Sun, Ying ^b   Cao, Yuan ^b   Li, Yaoming ^b   Li, Wenxin ^a   Guo, Deying ^a   Cao, Zhijian ^a   Yan, Huimin ^a,b  

^a WUHAN UNIVERSITY   (China)

^b WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; PEPTIDE DERIVATIVE; PROTEIN KN2-7; SCORPION VENOM; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; KN2 7 PEPTIDE; KN2-7 PEPTIDE;

ANTI HIV 1 ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PSEUDOTYPING; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN; AMINO ACID SEQUENCE; CELL LINE; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN SECONDARY STRUCTURE; SYNTHESIS;

CERCOPITHECINE HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1; MEASLES VIRUS; RNA VIRUSES; SARS CORONAVIRUS; SCORPIONES;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SCORPION VENOMS;

EID: 84859856700     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034947     Document Type: Article

References (60)

1. UNAIDS, (2010) 23 UNAIDS Report on the Global AIDS Epidemic 2010.Available: http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf. Accessed 2010 Nov.
2. Titti F, Cafaro A, Ferrantelli F, Tripiciano A, Moretti S, et al. (2007) Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opin Emerg Drugs 12: 23-48.
3. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
5. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, et al. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763-767.
6. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, et al. (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666.
7. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, et al. (1996) A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85: 1149-1158.
8. Feng Y, Broder CC, Kennedy PE, Berger EA, (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877.
9. Neurath AR, Strick N, Li YY, (2002) Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infect Dis 2: 27.
10. Telwatte S, Moore K, Johnson A, Tyssen D, Sterjovski J, et al. (2011) Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Research 90: 195-199.
11. Torre VS, Marozsan AJ, Albright JL, Collins KR, Hartley O, et al. (2000) Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J Virol 74: 4868-4876.
12. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, et al. (2010) PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376: 1329-1337.
13. Pearce-Pratt R, Phillips DM, (1996) Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol Reprod 54: 173-182.
14. Tao J, Hu Q, Yang J, Li R, Li X, et al. (2007) In vitro anti-HIV and-HSV activity and safety of sodium rutin sulfate as a microbicide candidate. Antiviral Res 75: 227-233.
15. Vzorov AN, Bozja J, Dixon DW, Marzilli LG, Compans RW, (2007) Parameters of inhibition of HIV-1 infection by small anionic microbicides. Antiviral Res 73: 60-68.
16. Tao W, Richards C, Hamer D, (2008) Enhancement of HIV infection by cellulose sulfate. AIDS Res Hum Retroviruses 24: 925-929.
17. Boman HG, (2000) Innate immunity and the normal microflora. Immunol Rev 173: 5-16.
18. Hancock RE, Lehrer R, (1998) Cationic peptides: a new source of antibiotics. Trends Biotechnol 16: 82-88.
19. Fjell CD, Hancock RE, Cherkasov A, (2007) AMPer: a database and an automated discovery tool for antimicrobial peptides. Bioinformatics 23: 1148-1155.
20. Jenssen H, Hamill P, Hancock RE, (2006) Peptide antimicrobial agents. Clin Microbiol Rev 19: 491-511.
21. Martin E, Ganz T, Lehrer RI, (1995) Defensins and other endogenous peptide antibiotics of vertebrates. J Leukoc Biol 58: 128-136.
22. Wang Z, Wang G, (2004) APD: the Antimicrobial Peptide Database. Nucleic Acids Res 32: D590-592.
23. Zasloff M, (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 389-395.
24. Ma Y, Zhao R, He Y, Li S, Liu J, et al. (2009) Transcriptome analysis of the venom gland of the scorpion Scorpiops jendeki: implication for the evolution of the scorpion venom arsenal. BMC Genomics 10: 290.
25. Possani LD, Merino E, Corona M, Bolivar F, Becerril B, (2000) Peptides and genes coding for scorpion toxins that affect ion-channels. Biochimie 82: 861-868.
26. Zhijian C, Feng L, Yingliang W, Xin M, Wenxin L, (2006) Genetic mechanisms of scorpion venom peptide diversification. Toxicon 47: 348-355.
27. Torres-Larios A, Gurrola GB, Zamudio FZ, Possani LD, (2000) Hadrurin, a new antimicrobial peptide from the venom of the scorpion Hadrurus aztecus. Eur J Biochem 267: 5023-5031.
28. Conde R, Zamudio FZ, Rodriguez MH, Possani LD, (2000) Scorpine, an anti-malaria and anti-bacterial agent purified from scorpion venom. FEBS Lett 471: 165-168.
29. Moerman L, Bosteels S, Noppe W, Willems J, Clynen E, et al. (2002) Antibacterial and antifungal properties of alpha-helical, cationic peptides in the venom of scorpions from southern Africa. Eur J Biochem 269: 4799-4810.
30. Dai L, Yasuda A, Naoki H, Corzo G, Andriantsiferana M, et al. (2001) IsCT, a novel cytotoxic linear peptide from scorpion Opisthacanthus madagascariensis. Biochem Biophys Res Commun 286: 820-825.
31. Dai C, Ma Y, Zhao Z, Zhao R, Wang Q, et al. (2008) Mucroporin, the first cationic host defense peptide from the venom of Lychas mucronatus. Antimicrob Agents Chemother 52: 3967-3972.
32. Zhao Z, Ma Y, Dai C, Zhao R, Li S, et al. (2009) Imcroporin, a new cationic antimicrobial peptide from the venom of the scorpion Isometrus maculates. Antimicrob Agents Chemother 53: 3472-3477.
33. Albiol Matanic VC, Castilla V, (2004) Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int J Antimicrob Agents 23: 382-389.
34. Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, et al. (2005) Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol 79: 14318-14329.
35. Carriel-Gomes MC, Kratz JM, Barracco MA, Bachere E, Barardi CR, et al. (2007) In vitro antiviral activity of antimicrobial peptides against herpes simplex virus 1, adenovirus, and rotavirus. Mem Inst Oswaldo Cruz 102: 469-472.
36. Yan R, Zhao Z, He Y, Wu L, Cai D, et al. (2011) A new natural alpha-helical peptide from the venom of the scorpion Heterometrus petersii kills HCV. Peptides 32: 11-19.
37. Mohan KV, Rao SS, Atreya CD, (2010) Antiviral activity of selected antimicrobial peptides against vaccinia virus. Antiviral Res 86 (3): 306-311.
38. Li Q, Zhao Z, Zhou D, Chen Y, Hong W, et al. (2011) Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides 32: 1518-1525.
39. Zeng XC, Wang SX, Zhu Y, Zhu SY, Li WX, (2004) Identification and functional characterization of novel scorpion venom peptides with no disulfide bridge from Buthus martensii Karsch. Peptides 25: 143-150.
40. Rost B, Sander C, (1993) Prediction of protein secondary structure at better than 70% accuracy. Journal of Molecular Biology 232: 584-584.
41. Cory A, Owen T, Barltrop J, Cory J, (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer communications 3: 207.
42. Choudhry V, Zhang MY, Sidorov IA, Louis JM, Harris I, et al. (2007) Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363: 79-90.
43. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, et al. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377.
44. Arien KK, Jespers V, Vanham G, (2011) HIV sexual transmission and microbicides. Rev Med Virol 21 (2): 110-133.
45. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. Journal of Virology 79: 10108-10125.
46. Cole AL, Yang OO, Warren AD, Waring AJ, Lehrer RI, et al. (2006) HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41. The Journal of Immunology 176: 6900.
47. Brogden KA, (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3: 238-250.
48. Oren Z, Shai Y, (1998) Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 47: 451-463.
49. Ehrenstein G, Lecar H, (1977) Electrically gated ionic channels in lipid bilayers. Quarterly reviews of biophysics 10: 1-34.
50. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
51. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
52. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
53. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, et al. (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59: 284-291.
54. Hamilton MA, McKenzie-Pollock M, Heath ME, (1977) The treatment and prevention of chronic otorrhoea in the Northland health district. N Z Med J 86: 327-329.
55. Sakai K, Ma XY, Gordienko I, Volsky DJ, (1991) Recombinational analysis of a natural noncytopathic human immunodeficiency virus type 1 (HIV-1) isolate: role of the vif gene in HIV-1 infection kinetics and cytopathicity. J Virol 65: 5765-5773.
56. Montefiori DC, (2005) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12: Unit 12 11.
57. Zhang Y, Yang J, Bao R, Chen Y, Zhou D, et al. (2011) Unpolarized release of vaccinia virus and HIV antigen by colchicine treatment enhances intranasal HIV antigen expression and mucosal humoral responses. PLoS ONE 6: e24296.
58. Abdiche Y, Malashock D, Pinkerton A, Pons J, (2008) Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Analytical Biochemistry 377: 209-217.
59. Do T, Ho F, Heidecker B, Witte K, Chang L, et al. (2008) A rapid method for determining dynamic binding capacity of resins for the purification of proteins. Protein Expr Purif 60: 147-150.
60. Reed LJ, Muench H, (1938) A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology 27: 493.